中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(8): 1768-1773

Value of external validation of REAL-B score in predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients treated by antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2022.08.010
  • 1.

    Clinical College of The Second People's Hospital, Tianjin Medical University, Tianjin 300070, China

  • 2.

    Tianjin Hepatopathy Research Institute, Tianjin Second People's Hospital, Tianjin 300192, China

Research funding:

Wang Bao'en Liver Fibrosis Research Fund of China Hepatitis Prevention foundation (2021038)

More Information
  • Corresponding author: LI Ping, tjlplxg@163.com(ORCID: 0000-0001-9930-6429)
  • Received Date: 2021-12-19
  • Accepted Date: 2022-01-20
  • Published Date: 2022-08-20
    Abstract
  •   Objective  To investigate the value of the hepatocellular carcinoma (HCC) risk model REAL-B score in predicting the risk of HCC in chronic hepatitis B (CHB) patients receiving antiviral therapy in comparison with mPAGE-B, aMAP and PAGE-B scores.  Methods  A retrospective analysis was performed for the clinical data of 1160 CHB patients who received entecavir or tenofovir treatment for more than 1 year from January 2013 to December 2015 in Tianjin Second Peolple's Hospital, and the events of HCC were recorded. The area under the ROC curve (AUC) was used to evaluate the value of REAL-B, mPAGE-B, aMAP, and PAGE-B scores in predicting HCC. The Kaplan-Meier method was used to evaluate the cumulative incidence rate of HCC at different time points, and the log-rank test was used to compare the incidence rate of HCC between the groups with different scores. The independent samples t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups.  Results  Among the 1160 CHB patients, 108 (9.8%) progressed to HCC within a median follow-up time of 5.3 (5.0-6.3) years. REAL-B score had an AUC of 0.848 (95% confidence interval [CI]: 0.816-0.880) in predicting the onset of HCC within 5 years, followed by aMAP score (AUC=0.823, 95% CI: 0.786-0.860), mPAGE-B score (AUC=0.822, 95%CI: 0.788-0.857), and PAGE-B scores (AUC=0.780, 95%CI: 0.736-0.824). The 5-year cumulative incidence rate of HCC was 0.8% in the low-risk group (with a REAL-B score of 0-3 points), which was significantly lower than the incidence rate of 11.8% in the medium-risk group (with a REAL-B score of 4-7 points) and 35.6% with the high-risk group (with a REAL-B score of 8-13 points) (P < 0.05). In the low-risk group, REAL-B score had a negative predictive value of 100% and 99.67%, respectively, in predicting HCC within 3 and 5 years.  Conclusion  REAL-B score accurately predicts the risk of HCC in CHB patients receiving antiviral therapy, with a better predictive value than the other risk models within 3 years of antiviral therapy.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
    [2]
    BOCKMANN JH, KOHSAR M, MURRAY JM, et al. High rates of liver cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients with metabolic and cardiovascular comorbidities[J]. Microorganisms, 2021, 9(5): 968. DOI: 10.3390/microorganisms9050968.
    [3]
    SINGAL AK, SALAMEH H, KUO YF, et al. Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2013, 38(2): 98-106. DOI: 10.1111/apt.12344.
    [4]
    CHEN BW, ZHU XJ, ZHANG X, et al. Influence of virologic response on disease progression in patients with compensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014.

    陈博武, 朱晓骏, 张鑫, 等. 病毒学应答状态对代偿期乙型肝炎肝硬化患者疾病进展的影响[J]. 临床肝胆病杂志, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014.
    [5]
    KIM SU, SEO YS, LEE HA, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: A multicenter study[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(4): 832-837. DOI: 10.1158/1055-9965.EPI-19-0614.
    [6]
    PAPATHEODORIDIS GV, DALEKOS GN, IDILMAN R, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 73(5): 1037-1045. DOI: 10.1016/j.jhep.2020.06.011.
    [7]
    SOU FM, HU TH, HUNG CH, et al. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients[J]. Hepatol Int, 2020, 14(4): 513-520. DOI: 10.1007/s12072-020-10031-3.
    [8]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [9]
    European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma[J]. Eur J Cancer, 2012, 48(5): 599-641. DOI: 10.1016/j.ejca.2011.12.021.
    [10]
    LEE HW, YOO EJ, KIM BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J]. Am J Gastroenterol, 2014, 109(8): 1241-1249. DOI: 10.1038/ajg.2014.157.
    [11]
    PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4): 800-806. DOI: 10.1016/j.jhep.2015.11.035.
    [12]
    FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6): 1368-1378. DOI: 10.1016/j.jhep.2020.07.025.
    [13]
    KIM JH, KIM YD, LEE M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5): 1066-1073. DOI: 10.1016/j.jhep.2018.07.018.
    [14]
    HSU YC, YIP TC, HO HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2): 278-285. DOI: 10.1016/j.jhep.2018.02.032.
    [15]
    YANG HI, YEH ML, WONG GL, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3): 389-399. DOI: 10.1093/infdis/jiz477.
    [16]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [17]
    ZHOU J, SUN H, WANG Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Liver Cancer, 2020, 9(6): 682-720. DOI: 10.1159/000509424.
    [18]
    LIU L, SHI K, ZHANG Q, et al. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(7): 1591-1593. DOI: 10.3969/j.issn.1001-5256.2021.07.022.

    刘龙, 时克, 张群, 等. 慢性乙型肝炎患者发生肝细胞癌的危险因素分析[J]. 临床肝胆病杂志, 2021, 37(7): 1589-1593. DOI: 10.3969/j.issn.1001-5256.2021.07.022.
    [19]
    LEE HW, KIM SU, PARK JY, et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy[J]. Liver Int, 2019, 39(9): 1624-1630. DOI: 10.1111/liv.14129.
    [20]
    KIM MN, HWANG SG, RIM KS, et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir[J]. Liver Int, 2017, 37(12): 1788-1795. DOI: 10.1111/liv.13450.
    [21]
    PAPATHEODORIDIS GV, SYPSA V, DALEKOS GN, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(6): 1088-1096. DOI: 10.1016/j.jhep.2020.01.007.
    [22]
    WONG GL, CHAN HL, WONG CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol, 2014, 60(2): 339-345. DOI: 10.1016/j.jhep.2013.09.029.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (525) PDF downloads(69) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return